Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers

NCT02844582 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT02844582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02844582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Terminated
Start date
December 20, 2017
Completion date
June 4, 2019
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, stage iv prostate adenocarcinoma